On the surface of it a 0.55p share bid for Yourgene (YGEN) by Novacyt (NCYT) looks like a mercy killing, a good result in bad circumstances and a deal that should be done and dusted. But is it?
On 21st December, with its shares having previously closed at 1.85p, Yourgene Health* (YGEN) announced a “capital raising” for “not less than £5.0 million” stated to “provide near-term working capital; and facilitate further restructuring of the group's cost base, removing £2.0 million of annual operating expenditure. The company will also utilise any additional net proceeds to fund regulatory approvals and existing product enhancements”. I.e. it was cash crunch ahoy and, having left the fundraise to that point and with stock market conditions dreadful, the raising was at… 0.30p per share! Unsurprisingly, that sunk the shares, but with new capital now raised and sentiment arguably having hit rock bottom, we see some good recovery potential from a current 0.38p offer price. (now 0.41p)
Back on 14 October when Yourgene (YGEN) shares traded at 4,25p I warned that the company would almost certainly run out of cash and would need to do a fund raise, HERE
Once upon a time, Yourgene (YGEN) was a growth stock, the sort of company where shoot the lights out sales increases justified a lofty multiple which might allow for yet another fund raise. How times have changed. Today’s trading update was piss poor and, whatever bearded boss Lynn Rees might say, there must be a very high chance of a 2023 placing, as I warned three weeks ago HERE.
A trading update from Yourgene Health (YGEN) commences that “the stronger trading patterns being observed in H2 compared to the first 6 months of the financial year mean that double-digit revenue growth is expected for the full year” (to 31st March 2021). However, the shares are currently around 9% lower in response, at circa 12p, with the update also including “the ongoing impact of COVID-19 on ordering patterns in UK and international commerce is expected to result in full year revenue being below consensus market estimates”. Having spoken to the company, here’s the detail...
A “Contract manufacturing agreement for COVID-19 test” announcement from Yourgene Health (YGEN) – and the shares currently more than 30% higher on the back of it, to 15.75p…
Yourgene Health (YGEN) has announced Elucigene DPYD has been approved for sale in Australia – and the shares have currently responded slightly higher, further towards 15p…
Yourgene Health (YGEN) has announced results for its half-year ended 30th September 2019 and that “at this interim stage we are firmly on target to deliver full year results in-line with market expectations, with consensus analyst forecasts looking for revenues of nearly £17m for the year ending 31 March 2020, a considerable jump from last year's £8.9m”…
